07:35 AM EDT, 07/10/2024 (MT Newswires) -- An analysis of US pharmacy claims provided to Reuters showed most patients stop using Novo Nordisk's ( NVO ) Wegovy or Ozempic after two years, Reuters reported.

The analysis conducted by Prime Therapeutics and Magellan Rx Management showed only one in four patients prescribed the drugs for obesity continues with the medication after two years, and the decline in use is steady thereafter, Reuters said. The analysis did not disclose details of why patients stopped taking the drugs.

Novo Nordisk ( NVO ) cited the analysis' limitations in a statement, Reuters said, noting of the two drugs originally prescribed for Type 2 diabetes, Ozempic is not approved for weight loss while Wegovy was only launched around the middle of the study period, in June 2021. The company said the analysis' data are not enough basis for conclusions on overall patient adherence to the drugs' prescriptions, Reuters added.

Reuters also said the analysis did not assess the long-term use of Eli Lilly's (LLY) weight-loss drugs Mounjaro and Zepbound.

Novo Nordisk ( NVO ) and Eli Lilly did not immediately respond to MT Newswires' requests for comments.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 139.45, Change: -0.98, Percent Change: -0.70